Cargando…
Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET
Introduction: The gastrin-releasing peptide receptor (GRPR) is overexpressed in breast cancer. The present study evaluates GRPR imaging as a novel imaging modality in breast cancer by employing positron emission tomography (PET) and the GRPR antagonist (68)Ga-RM2. Methods: Fifteen female patients wi...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955063/ https://www.ncbi.nlm.nih.gov/pubmed/27446498 http://dx.doi.org/10.7150/thno.14958 |
_version_ | 1782443885196214272 |
---|---|
author | Stoykow, Christian Erbes, Thalia Maecke, Helmut R Bulla, Stefan Bartholomä, Mark Mayer, Sebastian Drendel, Vanessa Bronsert, Peter Werner, Martin Gitsch, Gerald Weber, Wolfgang A Stickeler, Elmar Meyer, Philipp T |
author_facet | Stoykow, Christian Erbes, Thalia Maecke, Helmut R Bulla, Stefan Bartholomä, Mark Mayer, Sebastian Drendel, Vanessa Bronsert, Peter Werner, Martin Gitsch, Gerald Weber, Wolfgang A Stickeler, Elmar Meyer, Philipp T |
author_sort | Stoykow, Christian |
collection | PubMed |
description | Introduction: The gastrin-releasing peptide receptor (GRPR) is overexpressed in breast cancer. The present study evaluates GRPR imaging as a novel imaging modality in breast cancer by employing positron emission tomography (PET) and the GRPR antagonist (68)Ga-RM2. Methods: Fifteen female patients with biopsy confirmed primary breast carcinoma (3 bilateral tumors; median clinical stage IIB) underwent (68)Ga-RM2-PET/CT for pretreatment staging. In vivo tumor uptake of (68)Ga-RM2 was correlated with estrogen (ER) and progesterone (PR) receptor expression, HER2/neu status and MIB-1 proliferation index in breast core biopsy specimens. Results: 13/18 tumors demonstrated strongly increased (68)Ga-RM2 uptake compared to normal breast tissue (defined as PET-positive). All PET-positive primary tumors were ER- and PR-positive (13/13) in contrast to only 1/5 PET-negative tumors. Mean SUV(MAX) of ER-positive tumors was 10.6±6.0 compared to 2.3±1.0 in ER-negative tumors (p=0.016). In a multivariate analysis including ER, PR, HER2/neu and MIB-1, only ER expression predicted (68)Ga-RM2 uptake (model: r(2)=0.55, p=0.025). Normal breast tissue showed inter- and intraindividually variable, moderate GRPR binding (SUV(MAX) 2.3±1.0), while physiological uptake of other organs was considerably less except pancreas. Of note, (68)Ga-RM2-PET/CT detected internal mammary lymph nodes with high (68)Ga-RM2 uptake (n=8), a contralateral axillary lymph node metastasis (verified by biopsy) and bone metastases (n=1; not detected by bone scan and CT). Conclusion: Our study demonstrates that (68)Ga-RM2-PET/CT is a promising imaging method in ER-positive breast cancer. In vivo GRPR binding assessed by (68)Ga-RM2-PET/CT correlated with ER expression in primary tumors of untreated patients. |
format | Online Article Text |
id | pubmed-4955063 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-49550632016-07-21 Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET Stoykow, Christian Erbes, Thalia Maecke, Helmut R Bulla, Stefan Bartholomä, Mark Mayer, Sebastian Drendel, Vanessa Bronsert, Peter Werner, Martin Gitsch, Gerald Weber, Wolfgang A Stickeler, Elmar Meyer, Philipp T Theranostics Research Paper Introduction: The gastrin-releasing peptide receptor (GRPR) is overexpressed in breast cancer. The present study evaluates GRPR imaging as a novel imaging modality in breast cancer by employing positron emission tomography (PET) and the GRPR antagonist (68)Ga-RM2. Methods: Fifteen female patients with biopsy confirmed primary breast carcinoma (3 bilateral tumors; median clinical stage IIB) underwent (68)Ga-RM2-PET/CT for pretreatment staging. In vivo tumor uptake of (68)Ga-RM2 was correlated with estrogen (ER) and progesterone (PR) receptor expression, HER2/neu status and MIB-1 proliferation index in breast core biopsy specimens. Results: 13/18 tumors demonstrated strongly increased (68)Ga-RM2 uptake compared to normal breast tissue (defined as PET-positive). All PET-positive primary tumors were ER- and PR-positive (13/13) in contrast to only 1/5 PET-negative tumors. Mean SUV(MAX) of ER-positive tumors was 10.6±6.0 compared to 2.3±1.0 in ER-negative tumors (p=0.016). In a multivariate analysis including ER, PR, HER2/neu and MIB-1, only ER expression predicted (68)Ga-RM2 uptake (model: r(2)=0.55, p=0.025). Normal breast tissue showed inter- and intraindividually variable, moderate GRPR binding (SUV(MAX) 2.3±1.0), while physiological uptake of other organs was considerably less except pancreas. Of note, (68)Ga-RM2-PET/CT detected internal mammary lymph nodes with high (68)Ga-RM2 uptake (n=8), a contralateral axillary lymph node metastasis (verified by biopsy) and bone metastases (n=1; not detected by bone scan and CT). Conclusion: Our study demonstrates that (68)Ga-RM2-PET/CT is a promising imaging method in ER-positive breast cancer. In vivo GRPR binding assessed by (68)Ga-RM2-PET/CT correlated with ER expression in primary tumors of untreated patients. Ivyspring International Publisher 2016-06-19 /pmc/articles/PMC4955063/ /pubmed/27446498 http://dx.doi.org/10.7150/thno.14958 Text en © Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions. |
spellingShingle | Research Paper Stoykow, Christian Erbes, Thalia Maecke, Helmut R Bulla, Stefan Bartholomä, Mark Mayer, Sebastian Drendel, Vanessa Bronsert, Peter Werner, Martin Gitsch, Gerald Weber, Wolfgang A Stickeler, Elmar Meyer, Philipp T Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET |
title | Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET |
title_full | Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET |
title_fullStr | Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET |
title_full_unstemmed | Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET |
title_short | Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET |
title_sort | gastrin-releasing peptide receptor imaging in breast cancer using the receptor antagonist (68)ga-rm2 and pet |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955063/ https://www.ncbi.nlm.nih.gov/pubmed/27446498 http://dx.doi.org/10.7150/thno.14958 |
work_keys_str_mv | AT stoykowchristian gastrinreleasingpeptidereceptorimaginginbreastcancerusingthereceptorantagonist68garm2andpet AT erbesthalia gastrinreleasingpeptidereceptorimaginginbreastcancerusingthereceptorantagonist68garm2andpet AT maeckehelmutr gastrinreleasingpeptidereceptorimaginginbreastcancerusingthereceptorantagonist68garm2andpet AT bullastefan gastrinreleasingpeptidereceptorimaginginbreastcancerusingthereceptorantagonist68garm2andpet AT bartholomamark gastrinreleasingpeptidereceptorimaginginbreastcancerusingthereceptorantagonist68garm2andpet AT mayersebastian gastrinreleasingpeptidereceptorimaginginbreastcancerusingthereceptorantagonist68garm2andpet AT drendelvanessa gastrinreleasingpeptidereceptorimaginginbreastcancerusingthereceptorantagonist68garm2andpet AT bronsertpeter gastrinreleasingpeptidereceptorimaginginbreastcancerusingthereceptorantagonist68garm2andpet AT wernermartin gastrinreleasingpeptidereceptorimaginginbreastcancerusingthereceptorantagonist68garm2andpet AT gitschgerald gastrinreleasingpeptidereceptorimaginginbreastcancerusingthereceptorantagonist68garm2andpet AT weberwolfganga gastrinreleasingpeptidereceptorimaginginbreastcancerusingthereceptorantagonist68garm2andpet AT stickelerelmar gastrinreleasingpeptidereceptorimaginginbreastcancerusingthereceptorantagonist68garm2andpet AT meyerphilippt gastrinreleasingpeptidereceptorimaginginbreastcancerusingthereceptorantagonist68garm2andpet |